Clinical trials: TACE
Hepatocellular Carcinoma
The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Transarterial chemoembolization (TACE) is considered the gold standard for treating intermediate-stage hepatocellular carcinoma (HCC). However, any treatment guidelines do not specify the criteria for repeating TACE.
- Trial name
- NCT02220088
- Testing
- TAI of FOLFOX, Sorafenib
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC
This study is conducted to evaluate the efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) compared with conventional transarterial chemoembolization (cTACE) as the conversion therapy for unresectable large…
- Trial name
- NCT04967482
- Testing
- Drug-eluting bead transarterial chemoembolization (DEB-TACE), Conventional transarterial chemoembolization (cTACE)
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma
Pain is the main complication after TACE(Transcatheter Arterial Chemoembolization) for hepatocellular carcinoma, and its pathogenesis is not clear.The pain may be related to partial liver tissue swelling after blocking the tumor…
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Pain
- Trial name
- NCT05670561
- Testing
- Esketamine, Sufentanil
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
TACE, HCC - Hepatocellular Carcinoma
Prediction and Prognostic Analysis of Liver Abscess Formation After Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma (CHANCE 2407)
Liver abscess is a rare but serious complication of hepatocellular carcinoma after TACE, with an incidence of less than 1% reported in previous literature.
- Conditions
- TACE, HCC - Hepatocellular Carcinoma, Liver Abscess
- Trial name
- NCT06483594
- Volunteers
- 400 people
- Sponsor
- Shengjing Hospital
Huge Hepatocellular Carcinoma (HCC) (≥10cm)
Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm)
A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE combined with Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm).
- Trial name
- NCT04619329
- Testing
- GSMs-TACE, Surgical Resection
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Advanced Adult Primary Liver Cancer
Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE
To investigate the therapy effect and security of oxaliplatin and fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
- Trial name
- NCT02557503
- Testing
- Oxaliplatin and fluorouracil
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhu Xu
Hepatocellular Carcinoma, Metastasis
Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis
Sorafenib is the standard therapy for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). However, addition of transarterial chemoembolization (TACE) may be beneficial for controlling intrahepatic tumour.
- Trial name
- NCT03518502
- Testing
- transarterial chemoembolization (TACE), Sorafenib
- Where
- 6 sites in South Korea
- Volunteers
- 130 people
- Sponsor
- Korea University
Unresectable, Non-metastatic Hepatocellular Carcinoma
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
To evaluate the efficacy and safety of AK104 plus lenvatinib combined with on-demand TACE in participants with unresectable, non-metastatic hepatocellular carcinoma
- Trial name
- NCT05319431
- Testing
- AK104, Lenvatinib, TACE
- Where
- 5 sites in China
- Volunteers
- 60 people
- Sponsor
- Akeso
HepatoCellular Carcinoma
Comparison of SBRTand Repeat TACE for HCC
Comparison of Stereotactic Body Radiation Therapy (SBRT) and repeated transarterial chemoembolization (TACE) for Hepatocellular Carcinoma (HCC)as a Local Salvage Treatment after first incomplete TACE
- Trial name
- STH (NCT03326375)
- Testing
- SBRT
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gangneung Asan Hospital
HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases.
- Conditions
- HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
- Trial name
- DAWNbreak-120 (NCT07691645)
- Testing
- Shuganhuazhuo Formula, Targeted therapy, Immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiang-Qian
Hepatocellular Carcinoma
Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma
The purpose of this observational study is to evaluate properties of lipiodol-idarubicin emulsion mixed with the best regimen obtained in vitro study, including stability, viscosity，visibility under X-ray and deposition, in order…
- Trial name
- NCT05631613
- Testing
- cTACE(conventional transarterial chemoembolization)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongda Hospital
HCC, Hepatocellular Carcinoma
LifePearl-Doxo Pharmacokinetic (PK) Study
The primary purpose of the study is to evaluate the pharmacokinetic profile, safety, and efficacy of LifePearl™ microspheres loaded with Doxorubicin in the treatment of unresectable HCC.
- Trial name
- NCT02548780
- Testing
- Chemoembolization, Pharmacokinetics
- Where
- 3 sites in Greece, Spain and 1 more
- Volunteers
- 15 people
- Sponsor
- Terumo Europe N.V.
Hepatocellular Carcinoma, Liver Cancer
TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma
Little is known about whether the types of chemotherapeutic agents affect the efficacy of transarterial chemoembolization in patients with hepatocellular carcinoma.
- Trial name
- IDADOX (NCT06114082)
- Testing
- IDA-TACE, DOX-TACE
- Where
- South Korea
- Volunteers
- 128 people
- Sponsor
- Seoul National University Hospital
Advanced Hepatocellular Carcinoma
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of TAC-101 after Transcatheter Arterial Chemoembolization (TACE) in patients with advanced, unresectable hepatocellular carcinoma (HCC) who are being scheduled for…
- Trial name
- NCT00756782
- Testing
- TAC-101
- Sponsor
- Taiho Oncology, Inc.
Hepatocellular Carcinoma
A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
The aim of this study is to analyze the therapeutic effect of adjuvant TACE after resection.Patients receiving curative resection (R0) were randomized to postoperative TACE group and no TACE group.
- Trial name
- NCT00820053
- Testing
- epirubicin and lipiodol
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Advanced Hepatocellular Carcinoma
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
Compared to systemic therapy alone, conversion therapy is promising to improve the prognosis of patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05738616
- Testing
- Lenvatinib combined with TACE and Camrelizumab
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Wen Tianfu
Hepatocellular Carcinoma
Efficacy of Radiation Therapy and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma (HCC)
In this study, the investigators are to prospectively evaluate patient's survival, tumor response, and safety of RT followed by TACE in Child A patients with unilobar portal vein invasion.
- Trial name
- RTANDTACE (NCT01432314)
- Testing
- Radiation therapy, Transarterial chemoembolization
- Sponsor
- Asan Medical Center
Liver Cancer
DEB-TACE Treatment in 367 Liver Cancer Patients
Introduction:The drug-eluting beads transarterial chemoembolization (DEB-TACE) is introduced to better improve efficacy and reduce the systemic toxicity in liver cancer patients on account of its higher intratumoral…
- Trial name
- NCT03317483
- Volunteers
- 367 people
- Sponsor
- Zhejiang Cancer Hospital
Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most common cause of cancer-related death worldwide.
- Conditions
- Unresectable Hepatocellular Carcinoma, Transarterial Chemoembolization, Camrelizumab, Apatinib
- Trial name
- NCT06485466
- Testing
- TACE plus camrelizumab and apatinib, Camrelizumab and apatinib
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Guohui Xu
Hepatocellular Carcinoma (HCC)
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with icaritin
- Trial name
- NCT06644937
- Testing
- TACE combined with Acoradine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital